

Date :01-08-2022

To,  
Cooperate Relation Department  
The BSE LIMITED  
1't Floor, Phiroze leejeebhoy Towers,  
Dalal Street,  
Mumbai-400001

Script Code: 531210

Dear Sir/ Madam,

**Sub: Newspaper clipping of the Un-Audited Financial Results pursuant to Regulation 47(3) of SEBI (Listing obligations and Disclosure Requirements) Regulations, 2015 for the Quarter and Half Year Ended on 30<sup>th</sup> June, 2022.**

Please find enclosed herewith Newspaper clippings of Audited Financial Results for the quarter and year ended on **30<sup>th</sup> June, 2022** published in **FREE PRESS JOURNAL** and **NAVSHAKTI** on **31<sup>st</sup> July, 2022** in pursuance of Regulation 47(3) of SEBI (Listing obligations and Disclosure Requirements) Regulations, 2015, which were approved in the Board meeting held on **30<sup>th</sup> July, 2022**.

Kindly acknowledge the receipt of the same and update in your records.

Thanking you,

Yours faithfully,  
For Colinz Laboratories Ltd.,

  
Dr. Mani L. S.  
Director & Company Secretary  
DIN: 00825886



**Colinz Laboratories Limited**

CIN NO- L24200MH1986PLC041128

**Corp.Off.:** A/101, Pratik Estate, Next to Fortis Hospital, Mulund Link Road, P. Box No. 17339 Mumbai - 400 078. INDIA

E-mail : colinzlabs@yahoo.com / colinzlabs@gmail.com

Tel:- +91-22-2566 8002 / 8003 Fax :- +91-22-2566 8006

31/7/2022

\* FREE PRESS JOURNAL \*

THE FREE PRESS JOURNAL

**COLINZ LABORATORIES LIMITED.**A-101, Pratik Ind. Estate, Next to Fortis Hospital, Mulund-Goregaon Link Road, Mumbai - 400 078.  
(CIN NO : L24200MH1986PLC041128)**"EXTRACTS OF AUDITED RESULTS FOR THE QUARTER AND YEAR ENDED 30<sup>TH</sup> JUNE, 2022"**

S. No.	PARTICULARS	(Rs. in "Lacs")			
		QUARTER ENDED		YEAR ENDED	
		Un-Audited 30-Jun-22	Audited 30-Jun-20	Audited 31-Mar-22	Audited 31-Mar-22
1	Revenue from Operations	187.93	189.18	165.27	714.50
2	Net Profit/(Loss) for the period( before Tax, Exceptional and/or Extraordinary Items).	14.28	11.20	12.40	48.03
3	Net Profit/(Loss) for the period before Tax (after Exceptional and/or Extraordinary Items).	14.28	11.20	12.40	48.03
4	Net Profit/(Loss) for the period after Tax (after Exceptional and/or Extraordinary Items).	11.03	8.45	7.01	33.93
5	Total Comprehensive Income for the period (Comprising Profit/(Loss) for the period (after tax) and Other Comprehensive Income (Net of Tax).	4.98	13.11	3.80	39.61
6	Equity Share Capital (Face Value of Rs. 10/- each).	251.91	354.50	354.50	354.50
7	Earning Per Share (Face value of Rs. 10/- each) (not annulised) (in Rs.)				
	1) Basic	0.44	0.18	0.15	0.74
	2) Diluted	0.44	0.18	0.15	0.74

**NOTES :-**

- 1) The above Financial Results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 30<sup>th</sup> July, 2022.
- 2) The above is an extract of the detailed format of financial results filed with the Stock Exchange under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015. The full format of the Financial Results is available on the website of BSE at [www.bseindia.com](http://www.bseindia.com) and on the Company's website at [www.findoc-cll.in](http://www.findoc-cll.in).
- 3) The above results of the Company has been reviewed by the Statutory Auditors and they have issued a Limited Review Report on the same.

MUMBAI.  
30<sup>th</sup> July, 2022For and on behalf of the Board  
**COLINZ LABORATORIES LTD.**  
CIN NO : L24200MH1986PLC041128  
**Dr. MANI L. S.**  
(Director & Company Secretary)  
(DIN NO : 00825886)**WALCHAND PEOPLEFIRST LIMITED**

CIN : L74140MH1920PLC000791





31/7/2022

\* NAV SHAKTI \*

नवशक्ति। मुंबई, रविवार, ३१ जुलै २०२२

**COLINZ LABORATORIES LIMITED.**A-101, Pratik Ind. Estate, Next to Fortis Hospital, Mulund-Goregaon Link Road, Mumbai - 400 078.  
(CIN NO : L24200MH1986PLC041128)**" EXTRACTS OF AUDITED RESULTS FOR THE QUARTER AND YEAR ENDED 30<sup>TH</sup> JUNE, 2022 "**  
(Rs. In "Lacs")

S. No.	PARTICULARS	QUARTER ENDED		YEAR ENDED	
		Un-Audited	Audited	Audited	
		30-Jun-22	30-Jun-20	31-Mar-22	31-Mar-22
1	Revenue from Operations	187.93	189.18	165.27	714.50
2	Net Profit/(Loss) for the period( before Tax, Exceptional and/or Extraordinary Items).	14.28	11.20	12.40	48.03
3	Net Profit/(Loss) for the period before Tax (after Exceptional and/or Extraordinary Items).	14.28	11.20	12.40	48.03
4	Net Profit/(Loss) for the period after Tax (after Exceptional and/or Extraordinary Items).	11.03	8.45	7.01	33.93
5	Total Comprehensive Income for the period (Comprising Profit/(Loss) for the period (after tax) and Other Comprehensive Income (Net of Tax).	4.98	13.11	3.80	39.61
6	Equity Share Capital (Face Value of Rs. 10/- each).	251.91	354.50	354.50	354.50
7	Earning Per Share (Face value of Rs. 10/- each) (not annulised) (in Rs.)				
	1) Basic	0.44	0.18	0.15	0.74
	2) Diluted	0.44	0.18	0.15	0.74

**NOTES:-**

- 1) The above Financial Results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 30<sup>th</sup> July, 2022.
- 2) The above is an extract of the detailed format of financial results filed with the Stock Exchange under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015. The full format of the Financial Results is available on the website of BSE at [www.bseindia.com](http://www.bseindia.com) and on the Company's website at [www.findoc-cll.in](http://www.findoc-cll.in).
- 3) The above results of the Company has been reviewed by the Statutory Auditors and they have issued a Limited Review Report on the same.

For and on behalf of the Board  
**COLINZ LABORATORIES LTD.**  
 CIN NO : L24200MH1986PLC041128  
**Dr. MANI L. S.**  
 (Director & Company Secretary)  
 (DIN NO : 00825886)

MUMBAI.  
 30<sup>th</sup> July, 2022

